Targets › ARAF
4 programs from 4 companies in 9 trials: 5 Phase 2, 3 Phase 1, 1 Phase 3; Oncology; next expected readout Dec 2026.
Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May also regulate the TOR signaling cascade. (UniProt, P10398)
Open in Phaseline: the race on ARAF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Day One Biopharmaceuticals | Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 3 | Low-grade Glioma; Craniopharyngioma, Child; Recurrent Langerhans Cell Histiocytosis; Hairy Cell Leukemia | May 2027 |
| Hanmi Pharmaceutical Company | Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 2 | Advanced or Metastatic Melanoma | Sep 2029 |
| Roche | Belvarafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Melanoma; Primary Brain Tumor | Dec 2026 |
| Ipsen | Tovorafenib RAF serine/threonine protein kinase inhibitor | RAF1, BRAF, ARAF | Phase 1 | Low-grade Glioma | Jul 2030 |
Low-grade Glioma (3) Melanoma (1) Primary Brain Tumor (1) Craniopharyngioma, Child (1) Recurrent Langerhans Cell Histiocytosis (1) Hairy Cell Leukemia (1) Advanced or Metastatic Melanoma (1)
small molecule (3), mixed (1)
Roche (1) Day One Biopharmaceuticals (1) Ipsen (1) Hanmi Pharmaceutical Company (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.